Google Doubles Down on Spending as AI Fear Returns | Prof G Markets
TL;DR
Google's plan to nearly double capital expenditures to $180 billion reignited market fears over AI infrastructure costs, while software stocks cratered on existential business model concerns and the GLP-1 weight-loss market saw Eli Lilly surge as rival Novo Nordisk collapsed.
💰 Google's Massive AI Infrastructure Bet 3 insights
Record $400 billion annual revenue and 48% cloud growth
Google reported its first-ever $400 billion revenue year with cloud revenue accelerating to 48% growth, significantly beating 38% expectations.
Capex surge to $175-185 billion nearly doubles 2025 spending
The company announced plans to spend $55 billion more than consensus forecasted on AI infrastructure, causing an initial 7% after-hours stock drop before recovery.
Market digesting aggressive front-footed growth strategy
Analysts note that while heavy spending pressures near-term profits, these investments position Google for strong returns once the infrastructure build-out enters harvest mode after 2027.
💻 AI Anxiety Crushes Software Multiples 3 insights
Seat-based licensing models face existential threat
Investors are dumping software stocks over fears that AI automation will reduce workforce seats, directly threatening per-user revenue models at companies like Salesforce and ServiceNow.
AI agents displacing traditional software tools
New AI capabilities like Claude are replacing software functions entirely, forcing a 1-3 year period of uncertainty as the industry separates winners from losers.
Indiscriminate selling creates selective buying opportunities
The market's sell everything reaction to AI disruption may reward patient investors who identify companies that successfully adapt their competitive position with AI features.
💊 Weight Loss Drug Market Splits Dramatically 3 insights
Eli Lilly surges 10% on 43% revenue growth
Lilly raised 2026 guidance to $80 billion while rival Novo Nordisk warned of declining sales, sending the two stocks in opposite directions by nearly 30 percentage points.
Novo Nordisk struggles with pricing pressure and share loss
Novo's market share for injectables has slipped to 30-40% while facing Medicare price negotiations and competition from lower-priced alternatives.
Transition to oral therapies disrupts profitability
Novo's new oral pill costs roughly $150 monthly versus $300-500 for injectables, creating volume growth but severe revenue degradation that has erased all GLP-1 era stock gains.
Bottom Line
Despite market panic over massive AI spending and software disruption, patient investors with a 3-year horizon can find buying opportunities in companies making strategic infrastructure bets or adapting business models to AI, while avoiding those facing permanent obsolescence.
More from The Prof G Pod (Scott Galloway)
View all
Gary Stevenson: “Your Kids Will Be Poorer Than You” | Prof G Conversations
Economist Gary Stevenson argues that extreme wealth inequality—where the top 1% holds 32% of national wealth—requires aggressively taxing hoarded wealth through properly designed wealth taxes, warning that without intervention, younger generations face declining living standards in an "inheritocracy" where outcomes depend entirely on parental wealth rather than merit.
China Is BEATING the U.S. in Space?! | China Decode
China is executing a military-driven space strategy to 'control Earth by controlling space' through dual-use technologies like robotic servicing arms, while domestically facing a fiscal crisis as $2.1 trillion in generational wealth transfers completely untaxed amid extreme inequality and declining government revenues.
The Iran War Has No Exit — ft. Ian Bremmer | Prof G Conversations
Ian Bremmer analyzes the widening rift between UAE and Saudi Arabia following the former's shock OPEC exit, while explaining how Iran's unexpected military resilience has trapped the Trump administration in a war with no viable exit strategy despite mounting domestic pressure and fraying alliances.
The U.S. vs China AI Battle Is Getting Ugly | China Decode
The US-China AI rivalry has entered a new phase of industrial-scale IP theft accusations and blocked tech acquisitions, even as Wall Street banks like Goldman Sachs increasingly borrow in Chinese currency through booming offshore dim sum bond markets to exploit interest rate differentials.